person · Reporting owner

Gergel Ivan P.

Disclosed activity across 3 companies

Tapewire entity: 144908
SEC CIK: 0001328288

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NEKTAR THERAPEUTICSNKTR · Entity 4364	SVP & Chief Medical Officer	November 15, 2017	November 17, 2017
Neurotrope, Inc.NTRP · Entity 144906	Director	December 01, 2020	December 03, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEKTAR THERAPEUTICS

Report date November 15, 2017 · Filed November 17, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	61,575	Reported balance After 2017-11-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-11-15 · Grant · Acquired 20,000 · Balance 61,575 F1: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).
Common StockSEC Table I · non-derivative	Direct	56,553	Reported balance After 2017-11-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2017-11-16 · Disposition to issuer · Disposed 5,022 · Balance 56,553 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.41 · Expires 2024-12-12	Direct	50,000	Reported balance After 2017-11-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-15 · Grant · Acquired 50,000 · Balance 50,000 F5: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016). F6: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI). F7: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

F2: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F5: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F6: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F7: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

Neurotrope, Inc.

Report date December 01, 2020 · Filed December 03, 2020

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44	Direct	Reported balance After 2020-12-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-12-01 · Disposition to issuer · Disposed 7,813 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2020-12-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06	Direct	Reported balance After 2020-12-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82	Direct	Reported balance After 2020-12-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97	Direct	Reported balance After 2020-12-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-12-01 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Corium International, Inc.

Report date November 27, 2018 · Filed November 28, 2018

Section 16 reporting ended · disclosed 2018-11-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 · Expires 2024-12-03	Direct	Reported balance After 2018-11-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17	Direct	Reported balance After 2018-11-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 01, 2020 Filed Dec 3, 2020 21:42 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $0.97	Not disclosed	Disclosure SEC source: 0001104659-20-132157 · tm2037705d9_4seq1.xml · derivative · entry 5 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:42 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $0.82	Not disclosed	Disclosure SEC source: 0001104659-20-132157 · tm2037705d9_4seq1.xml · derivative · entry 4 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:42 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $4.06	Not disclosed	Disclosure SEC source: 0001104659-20-132157 · tm2037705d9_4seq1.xml · derivative · entry 3 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:42 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	10,000	Not disclosed Strike: $3.93	Not disclosed	Disclosure SEC source: 0001104659-20-132157 · tm2037705d9_4seq1.xml · derivative · entry 2 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:42 UTC	Neurotrope, Inc. NTRP · Entity 144906	Disposition to issuerStock Option (right to buy) · Derivative	7,813	Not disclosed Strike: $4.44	Not disclosed	Disclosure SEC source: 0001104659-20-132157 · tm2037705d9_4seq1.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,813 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document
November 24, 2020 Filed Nov 27, 2020 17:11 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $0.97	$0.00	Disclosure SEC source: 0001104659-20-130084 · tm2037145d9_4seq1.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document
March 20, 2020 Filed Mar 24, 2020 18:03 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001104659-20-037868 · tm2013506d6_4.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-20 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document
March 15, 2019 Filed Apr 15, 2019 17:00 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $4.06	$0.00	Disclosure SEC source: 0001144204-19-019707 · tv518870_form4.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document
January 22, 2019 Filed Jan 24, 2019 18:04 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.93	$0.00	Disclosure SEC source: 0001144204-19-002691 · tv511532_4.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-22 F1 · security: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document
December 13, 2018 Filed Dec 17, 2018 17:01 UTC	Neurotrope, Inc. NTRP · Entity 144906	GrantStock Option (right to buy) · Derivative	7,813	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001144204-18-064949 · tv509205_4.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,813 Underlying: Common Stock · 7,813 shares Expires 2028-12-13 F1 · shares: These securities were issued in connection with the Reporting Person's appointment as a non-employee director to the Issuer's board of directors. F2 · derivative.exercise_date: The stock options shall vest in equal daily installments over a three-year period beginning on the date of grant. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:53 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	$12.50 Strike: $11.59	$187,500.00	Disclosure SEC source: 0001567619-18-007067 · doc1.xml · derivative · entry 4 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-11-30 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:53 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	$12.50 Strike: $4.59	$187,500.00	Disclosure SEC source: 0001567619-18-007067 · doc1.xml · derivative · entry 3 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-12-21 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:53 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	12,000	$12.50 Strike: $7.19	$150,000.00	Disclosure SEC source: 0001567619-18-007067 · doc1.xml · derivative · entry 2 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-12-17 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
November 27, 2018 Filed Nov 28, 2018 19:53 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	20,000	$12.50 Strike: $5.79	$250,000.00	Disclosure SEC source: 0001567619-18-007067 · doc1.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-12-03 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
December 01, 2017 Filed Dec 5, 2017 19:39 UTC	Corium International, Inc. CORI · Entity 162158	GrantDirector Stock Option (Rigth to Buy) · Derivative	15,000	$0.00 Strike: $11.59	$0.00	Disclosure SEC source: 0001140361-17-045106 · doc1.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-11-30 F1 · derivative.exercise_date: The option vests as to 1/12th of the total number of shares on January 1, 2018 and then 1/12th monthly thereafter. Read SEC document
November 16, 2017 Filed Nov 17, 2017 23:03 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Disposition to issuerCommon Stock	5,022	$44.23	$222,123.06	Disclosure SEC source: 0001209191-17-061590 · doc4.xml · nonDerivative · entry 2 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,553 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
November 15, 2017 Filed Nov 17, 2017 23:03 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	GrantStock Option · Derivative	50,000	$0.00 Strike: $14.41	$0.00	Disclosure SEC source: 0001209191-17-061590 · doc4.xml · derivative · entry 3 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016). F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI). F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document
November 15, 2017 Filed Nov 17, 2017 23:03 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-061590 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,575 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI). Read SEC document
October 02, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionStock Option · Derivative	56,704	$0.00 Strike: $11.04	$0.00	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · derivative · entry 6 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,752 Underlying: Common Stock · 56,704 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The stock option pursuant to this transaction vests as follows: 25% of the shares subject to the option vested on May 19, 2015 and the remaining 75% of the shares vest in equal monthly installments over the three-year period thereafter based on the Reporting Person's continuous service to the issuer. Read SEC document
October 02, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	56,704	$24.21	$1,372,803.84	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · nonDerivative · entry 4 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,575 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $24.04 to $24.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
October 02, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionCommon Stock	56,704	$11.04	$626,012.16	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · nonDerivative · entry 3 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
September 29, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionStock Option · Derivative	43,296	$0.00 Strike: $11.04	$0.00	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · derivative · entry 5 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,456 Underlying: Common Stock · 43,296 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The stock option pursuant to this transaction vests as follows: 25% of the shares subject to the option vested on May 19, 2015 and the remaining 75% of the shares vest in equal monthly installments over the three-year period thereafter based on the Reporting Person's continuous service to the issuer. Read SEC document
September 29, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	43,296	$24.04	$1,040,835.84	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · nonDerivative · entry 2 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,575 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.04 to $24.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
September 29, 2017 Filed Oct 3, 2017 22:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionCommon Stock	43,296	$11.04	$477,987.84	Disclosure SEC source: 0001209191-17-055353 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
August 16, 2017 Filed Aug 18, 2017 23:02 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	1,997	$19.32	$38,582.04	Disclosure SEC source: 0001209191-17-049664 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,575 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.02 to $19.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
July 18, 2017 Filed Jul 20, 2017 21:08 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionStock Option · Derivative	54,920	$0.00 Strike: $11.04	$0.00	Disclosure SEC source: 0001209191-17-045842 · doc4.xml · derivative · entry 3 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,752 Underlying: Common Stock · 54,920 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 18, 2017 Filed Jul 20, 2017 21:08 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	54,920	$21.10	$1,158,812.00	Disclosure SEC source: 0001209191-17-045842 · doc4.xml · nonDerivative · entry 2 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,572 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.04 to $21.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
July 18, 2017 Filed Jul 20, 2017 21:08 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionCommon Stock	54,920	$11.04	$606,316.80	Disclosure SEC source: 0001209191-17-045842 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 12, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionStock Option · Derivative	36,691	$0.00 Strike: $11.04	$0.00	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · derivative · entry 6 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,672 Underlying: Common Stock · 36,691 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 12, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	36,691	$21.09	$773,813.19	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · nonDerivative · entry 4 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,572 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.04 to $21.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
July 12, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionCommon Stock	36,691	$11.04	$405,068.64	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · nonDerivative · entry 3 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 11, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionStock Option · Derivative	8,389	$0.00 Strike: $11.04	$0.00	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · derivative · entry 5 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,363 Underlying: Common Stock · 8,389 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 11, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	8,389	$21.04	$176,504.56	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · nonDerivative · entry 2 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,572 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.04 to $21.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
July 11, 2017 Filed Jul 14, 2017 00:01 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	Exercise / conversionCommon Stock	8,389	$11.04	$92,614.56	Disclosure SEC source: 0001209191-17-045121 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 16, 2017 Filed May 19, 2017 00:46 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	1,450	$19.55	$28,347.50	Disclosure SEC source: 0001209191-17-033766 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,572 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.31 to $19.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
February 16, 2017 Filed Feb 18, 2017 01:03 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	1,457	$13.14	$19,144.98	Disclosure SEC source: 0001209191-17-012403 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.94 to $13.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document
December 22, 2016 Filed Dec 27, 2016 18:27 UTC	Corium International, Inc. CORI · Entity 162158	GrantDirector Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.59	$0.00	Disclosure SEC source: 0001140361-16-090845 · doc1.xml · derivative · entry 1 Gergel Ivan P. · CIK 0001328288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-12-21 F1 · derivative.exercise_date: The option vests as to 1/12th of the total number of shares on January 22, 2017 and then 1/12th monthly thereafter. Read SEC document
December 13, 2016 Filed Dec 16, 2016 01:43 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	GrantStock Option · Derivative	50,000	$0.00 Strike: $12.24	$0.00	Disclosure SEC source: 0001209191-16-155517 · doc4.xml · derivative · entry 2 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document
December 13, 2016 Filed Dec 16, 2016 01:43 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-16-155517 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,479 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service. Read SEC document
November 16, 2016 Filed Nov 18, 2016 23:08 UTC	NEKTAR THERAPEUTICS NKTR · Entity 4364	SaleCommon Stock	848	$13.96	$11,838.08	Disclosure SEC source: 0001209191-16-151301 · doc4.xml · nonDerivative · entry 1 Gergel Ivan P. · CIK 0001328288 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,479 F1 · price: This transaction was executed in multiple trades at prices ranging from $13.71 to $14.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.